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Edited by Vladimir SkulachevAbstract Reactive nitrogen species and their by-products, such
as peroxynitrite, modulate many physiological functions of skel-
etal muscle. Peroxynitrite generation occuring under speciﬁc
conditions, such as inﬂammation, may also lead to skeletal mus-
cle dysfunction and pathologies. Arylamine N-acetyltransferases
(NATs) are xenobiotic-metabolizing enzymes (XMEs) involved
in the detoxiﬁcation and/or metabolic activation of several drugs
and chemicals. In addition to other XMEs, such as gluthatione
S-transferases or cytochromes P450, NAT enzymes are ex-
pressed in skeletal muscle. We show here that functional
NAT1 and NAT2 isoforms are expressed in mouse myotubes
and that peroxynitrite may impair their activity in these cells.
We show that this inactivation is likely due to the irreversible
modiﬁcation of NATs catalytic cysteine residue in vivo. Our re-
sults suggest that peroxynitrite-dependent inactivation of muscle
XMEs such as NATs may contribute to muscle dysfunction by
impairing the biotransformation activity of this key cellular de-
fense enzyme system.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Reactive nitrogen species (RNS) and their by-products such
as peroxynitrite are known to have numerous physiological
functions in skeletal muscle cells. These functions include con-
traction, glucose uptake, metabolism and signaling [1–3].
However, under pathophysiological conditions such as inﬂam-
mation, excess production of these nitric oxide-derived oxi-
dants or failure of antioxidant systems contribute to muscle
dysfunction and pathologies through protein modiﬁcation
[1,4–6]. Despite the presence of key intracellular reductants,
such as reduced glutathione (GSH) or antioxidant enzymes
[1,3], excess peroxynitrite produced in inﬂamed skeletal muscle
has been shown to result in modiﬁcation of mitochondrial pro-Abbreviations: NAT, arylamine N-acetyltransferase; XME, xenobiotic-
metabolizing enzymes; SIN1, 3-morpholinosydnonimine N-ethylcar-
bamide
*Corresponding author. Fax: +33 1 44 27 69 99.
E-mail address: rlima@ext.jussieu.fr (F. Rodrigues-Lima).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.07.043teins, leading to mitochondrial dysfunction and contractile
failure [4]. Peroxynitrite may also be involved in muscle dys-
function through the inactivation of important muscle en-
zymes such as creatine kinase [7], sarcoplasmic reticulum
Ca2+-ATPase [3] and antioxidant enzymes [1]. Moreover,
chronic production of peroxynitrite in skeletal muscle during
aging processes has been shown to modify key enzymes in-
volved in muscle energy metabolism, leading to the decline
of motor function [5].
Arylamine N-acetyltransferases (NATs) are polymorphic
xenobiotic-metabolizing enzymes (XMEs) that catalyze the
acetyl-coenzyme A (AcCoA)-dependent N- and O-acetylation
of many arylamine drugs and toxic compounds [8,9]. These en-
zymes play a key role in detoxiﬁcation and the potential met-
abolic activation of many xenobiotics [10,11]. NATs are found
in diﬀerent eucaryotic and procaryotic species [11,12]. In hu-
mans, there are two highly similar NAT isoforms (81% iden-
tity). However, their substrate speciﬁcity proﬁles [9] and
tissue expression patterns diﬀer, with NAT1 considered as
being ubiquitously expressed [13,14]. The catalytic activity of
NAT enzymes depends on the presence of a reactive cysteine
residue. Modiﬁcation of this cysteine residue by certain chem-
icals, such as N-hydroxy-4-acetylaminobiphenyl [15], or by
biological oxidants [16–18] can lead to enzymatic inactivation.
In mice, there are three NAT isoforms. Murine NAT2 is con-
sidered the equivalent of human NAT1 in terms of substrate
speciﬁcity (acetylation of p-aminosalicylic acid, PAS) and
expression proﬁles, whereas murine NAT1 is closer to human
NAT2 (acetylation of sulfamethazine, SMZ) [19,20]. Murine
NAT3 has been detected in the spleen, but its activity towards
common NAT substrates is either low or undetectable [21].
We have previously shown in biopsy samples that NATs,
and more specially NAT1, are expressed in human skeletal
muscle suggesting that, in addition to other XMEs, such as
cytochromes P450 [22–24] and glutathione S-transferases
[25], the NAT-dependent biotransformation pathway occurs
in muscle.
In this study we show, using murine myoblast cells diﬀeren-
tiated as myotubes, that functional NAT1 and NAT2 enzymes
are present in skeletal muscle. We also show that peroxynitrite
leads to the irreversible impairment of the NAT enzymes bio-
transformation activity in myotubes through in vivo modiﬁca-
tion of their catalytic cysteine residue. Peroxynitrite-dependent
impairment of XMEs, such as NATs, in skeletal muscle may
increase the exposure of skeletal muscle to deleterious chemi-
cals that are transported through muscular blood ﬂow [29],blished by Elsevier B.V. All rights reserved.
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may sequester some therapeutic drugs [29], the impairment
of key XMEs such as NATs may have important consequences
on drug toxicity in muscles.Fig. 1. Endogenous activity of NATs in murine I28 and C2C12
myotubes. Equal amounts of I28 and C2C12 myotube protein extracts
were assayed for murine NAT1 (black bars) and NAT2 (grey bars)
activity. Normalization of the cell extracts was also checked by
Western blotting using an anti-desmin antibody (inset). The results
presented are the means of three independent experiments. Activity
was measured in triplicate. Error bars indicate standard deviation
(S.D.) values.2. Materials and methods
2.1. Materials
The Bradford protein assay kit was supplied by BioRad (France). P-
aminosalicylic acid (PAS), sulfamethazine (SMZ), acetyl-coenzyme A
(AcCoA), coenzyme A (CoA), 1,4-dithiothreitol (DTT), reduced gluta-
thione (GSH), 3-morpholinosydnonimine N-ethylcarbamide hydro-
chloride (SIN1) and polyclonal anti-3-nitrotyrosine antibodies were
obtained from Sigma (France). Polyclonal anti-human desmin anti-
bodies were obtained from Tebu (France). Peroxynitrite was obtained
from Calbiochem-Novabiochem Corporation (France). All other re-
agents were purchased from Sigma or Eurobio (France). Cell culture
products were from Gibco (France).
2.2. Cell culture
C2C12 and I28 cells are mouse myoblast cell lines that diﬀerentiate
rapidly, forming contractile myotubes and producing characteristic
skeletal muscle proteins [30,31]. Cells were cultured as monolayers in
100 mm Petri dishes at 37 C in Dulbecco modiﬁed Eagle medium
(DMEM) supplemented with 20% (v/v) fetal bovine serum and penicil-
lin/streptomycin. To prepare diﬀerentiated myotubes, the myoblasts
were switched to DMEM with 2% fetal bovine serum. The resulting
cultures showed >95% diﬀerentiated myotubes by visual examination.
2.3. Exposure of mouse myotubes to peroxynitrite and SIN1
At about 90% conﬂuence, myotubes monolayers were washed with
PBS. The cells were then exposed to peroxynitrite (250 and 500 lM
ﬁnal concentrations) or SIN1 (500 lM and 1 mM ﬁnal concentrations)
in 10 ml of serum-free PBS, with incubation at 37 C for 10 min (per-
oxynitrite) or 30 min (SIN1). Decomposed SIN1 (obtained by decom-
position in the dark at room temperature for 24 h), and PBS alone
were used as controls. Modiﬁcation of muscle proteins in peroxyni-
trite-treated myotubes was conﬁrmed by detection of 3-nitrotyrosine-
modiﬁed proteins in cell extracts using a speciﬁc anti-3-nitrotyrosine
antibody.
2.4. Determination of cellular NAT1 and NAT2 enzyme activity
Myotubes exposed to peroxynitrite or SIN1 were washed with PBS,
scraped into 800 ll of lysis buﬀer (20 mM Tris–HCl, pH 7.5, 0.1% Tri-
ton X-100, 1 mM EDTA and protease inhibitors), sonicated (three
pulses of 5 s), centrifuged for 15 min at 15000 · g and the supernatant
(cell extract) saved. The total protein concentration of the extracts was
determined with the Bradford assay. Extracts were adjusted to the
same protein concentration by addition of lysis buﬀer. Normalization
of cell extracts was also checked by Western-blotting with anti-desmin
antibody.
We assessed the ability of reducing agents to reactivate endogenous
inactivated NAT1 and NAT2 enzymes by incubating treated extracts
with GSH or DTT (5 and 10 mM ﬁnal concentrations) at 4 C for
20 min in a total volume of 50 ll before enzyme assays.
For substrate protection experiments, the cell extract was ﬁrst incu-
bated with various concentrations of AcCoA or CoA (0–2 mM ﬁnal
concentrations) at 37 C for 5 min. Samples were then treated with per-
oxynitrite as described, and then assayed.
The activities of endogenous mouse NAT1 and NAT2 enzymes were
detected in myotube extracts as described by Sinclair et al. [32], in a
total volume of 100 ll. Extracts (50 ll) and arylamine (200 lM PAS
or SMZ) in assay buﬀer (20 mM Tris–HCl, pH 7.5, 1 mM EDTA) were
incubated at 37 C for 5 min. We used PAS as the mouse NAT2-spe-
ciﬁc arylamine substrate, and SMZ as the mouse NAT1-speciﬁc aryl-
amine substrate. AcCoA (800 lM) was added to the reaction, and
the samples were incubated at 37 C for various lengths of time (up
to 30 min). The reaction was quenched by adding 100 ll of ice-cold
aqueous trichloroacetic acid (20% w/v), and the proteins were pelleted
by centrifugation for 5 min at 12000 · g. We added 4-dimethylamino-
benzaldehyde (DMAB; 800 ll, 5% w/v in 9/1 acetonitrile/water) andmeasured the absorbance at 405 nm. The amount of residual arylamine
was determined from a standard curve. All assays were performed in
triplicate, under conditions giving a linear initial rate. The enzyme
activities of the treated cell extracts were normalized based on protein
concentration and expressed as nmol of acetylated arylamine per min
per mg protein (nmol/min/mg) or as percentages of control NAT1
activity (control taken as 100% activity).
2.5. Statistical analysis
Data are expressed as the means ± S.D. of three independent exper-
iments, with triplicate assays performed for each experiment. We as-
sessed the statistical signiﬁcance of diﬀerences between means with
Students t-test. The level of signiﬁcance was set at P = 0.05.
2.6. Western blotting
For Western blotting, equal amounts of cellular proteins were sepa-
rated by SDS–PAGE and electrotransferred to a nitrocellulose mem-
brane. The membrane was blocked by incubation with Tris–buﬀered
saline/Tween 20 (TBS) supplemented with 5% nonfat milk powder
for 1 h. The primary antibody (polyclonal anti-desmin antibody or
polyclonal anti-3-nitrotyrosine antibody) was added and the mem-
brane incubated for a further 1 h 30 min in TBS (1% milk powder)
and then washed. The secondary conjugated antibody was added
and the membrane incubated for 1 h. The membrane was then washed
and the Supersignal reagent (Perbio Sciences, France) was used for
detection.3. Results and discussion
It has recently been shown that the xenobiotic-metabolizing
NAT enzymes are expressed in skeletal muscle [33]. It has also
been shown that the biotransformation activity of NAT en-
zymes is regulated by oxidants and cellular redox status [18].
In addition, peroxynitrite, a cellular nitric oxide-derived oxi-
dant may contribute to muscle dysfunction through protein
modiﬁcation and enzyme inactivation [3,4]. These data led us
to study whether peroxynitrite could impair the biotransfor-
mation activity of NAT enzymes in diﬀerentiated muscle cells.
Murine NAT2 activity was measured in extracts from C2C12
and I28 myotubes (5.52 ± 0.31 and 4.75 ± 0.4 nmol/min/mg,
respectively). Murine NAT1 activity, although lower, was also
Fig. 3. Eﬀect of reducing agents on peroxynitrite-dependent inactivation
of muscle NAT2 enzyme. The eﬀect of reducing agents on peroxynitrite-
inactivated NAT2 was studied as follows. Cells were ﬁrst exposed to
500 lM peroxynitrite for 30 min and a cellular extracts made. This
extract was then incubated with reducing agents (5 and 10 mM ﬁnal
concentrations of GSH or DTT) at 4 C for 20 min before measuring
activity. Results are presented as percent NAT2 activity. Error bars
indicate the S.D. values (\\P < 0.01 versus control (CTRL); # no
statistical diﬀerence with peroxynitrite traited sample (PN)).
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(Fig. 1). These results are consistent with previous data show-
ing that NAT2 activity in mice is higher than NAT1 activity
[21]. These data are also consistent with the expression of
NAT enzymes in human skeletal muscle [33] and that human
NAT1 activity in most tissues (which is equivalent to murine
NAT2) is higher than of human NAT2 activity (which is equiv-
alent of murine NAT1).
We measured the sensitivity of endogenous NAT enzymes to
peroxynitrite in murine C2C12 or I28 myotubes by exposing
cell monolayers to pathophysiologically-relevant amounts of
synthetic peroxynitrite (125, 250, 375 and 500 lM ﬁnal concen-
trations). High peroxynitrite concentrations (up to 500 lM)
have been detected in cells such as activated macrophages
[34,35].
Exposure of C2C12 myotubes to peroxynitrite led to the
dose-dependent impairment of endogenous NAT2 activity.
We obtained complete inactivation of muscular NAT2 with
500 lM peroxynitrite (Fig. 2). As peroxynitrite has a very
short half-life (<1 s) at pH 7.4 and 37 C we used SIN1, a com-
pound that releases peroxynitrite at a constant rate (peroxyni-
trite production from SIN1 is linear for up to 60 min at pH 7.4
and 37 C [36]), to mimic the constant physiological and
pathophysiological generation of peroxynitrite. Exposure of
myotubes to SIN1 (at 500, 750 and 1000 lM ﬁnal concentra-
tions) gave a signiﬁcant dose-dependent inactivation of endo-
genous NAT2 activity. The weaker but signiﬁcant inactivation
of NAT2 activity by SIN1 compared to peroxynitrite is prob-
ably because SIN1 produces lesser amounts of peroxynitrite
than the parent peroxynitrite donor [37]. Decomposed SIN1,
which does not release peroxynitrite, did not inactivate the
endogenous NAT2 enzyme. We obtained the same results
when assessing the NAT1 activity in myotubes. These data
show that peroxynitrite may impair the biotransformation
activity of NAT enzymes in myotubes.Fig. 2. Inactivation of endogenous NAT2 activity in murine C2C12
myotubes upon treatment with peroxynitrite and SIN1. C2C12 myotu-
bes were exposed to peroxynitrite or SIN1 in 10 ml of PBS at 37 C for
10 min. Cells were washed with PBS and a total protein extract
collected. NAT2 activity in normalized cell extracts was assessed using
DMAB. Normalization of the cell extracts assayed was also checked
by Western blotting with an anti-desmin antibody (inset). Extracts
from C2C12 cells exposed to PBS only were used as a control (CTRL).
The results presented are the means of three independent experiments.
Activity was measured in triplicate. Results are presented as percent
NAT2 activity. Error bars indicate standard deviation (S.D.) values
(\P < 0.05 versus control; \\P < 0.01 versus control).Peroxynitrite-dependent modiﬁcation of muscle enzymes
can lead to their irreversible inhibition [7,38]. Therefore,
we treated myotubes with peroxynitrite (500 lM ﬁnal con-
centration) and then preincubated the subsequent cell extract
with high concentrations of GSH or DTT (5 and 10 mM
ﬁnal concentrations). These two reducing agents were unable
to reactivate endogenous NAT2 (Fig. 3) and NAT1 (data
not shown). These data show that the biotransformation
activity of NAT enzymes in skeletal muscle cells may be
irreversibly impaired by peroxynitrite. It has been shown
in vitro using recombinant enzymes that NATs are irrevers-
ibly inactivated by peroxynitrite through oxidation of their
catalytic cysteine residue to sulﬁnic or sulfonic forms
[17,18,41]. In addition, chemical modiﬁcation of tyrosine res-
idues of NATs does not impair the catalytic activity of these
enzymes indicating that tyrosine nitration is unlikely to be
involved in the peroxynitrite-dependent inhibition of NATs
[17,18]. The catalytic activity of NATs depends on a reactive
cysteine residue present in a catalytic triad [9]. In addition,
site-directed mutagenesis experiments have shown that
replacement of the other cysteine residues has no eﬀect on
the catalytic activity of these enzymes [9,41]. Therefore, we
tested whether the irreversible inhibition of NATs by perox-
ynitrite in muscle cells was due to the modiﬁcation of their
catalytic cysteine residue. To this end, a ‘‘catalytic-cysteine
protection assay’’ used in several studies [16,17,41,42] was
carried out with AcCoA (the physiological acetyl-donor sub-
strate of NAT enzymes) and CoA (a product of AcCoA
hydrolysis). This assay relies upon the fact that AcCoA acet-
ylates speciﬁcally the catalytic cysteine residue of NAT en-
zymes (forming a covalent acetyl-enzyme complex) which
protects this residue from further chemical modiﬁcation
[9,18,42]. On the contrary CoA is unable to acetylate the
catalytic cysteine residue, this residue being therefore suscep-
tible to chemical modiﬁcation after preincubation with CoA
[9,18,39,42]. Myotube extracts were treated with peroxyni-
trite in presence of diﬀerent concentrations of AcCoA and
Fig. 4. Eﬀect of AcCoA or CoA preincubation against peroxynitrite-
dependent impairment of muscle NAT2 enzyme. A C2C12 myotube
protein extract was preincubated with diﬀerent concentrations
(0–2 mM ﬁnal) of AcCoA (squares) and CoA (triangles) prior to
exposure to 500 lM peroxynitrite for 10 min prior to NAT2 activity
measurement. Error bars indicate standard deviation (S.D.) values
(\P < 0.05 versus control (no AcCoA/CoA); \\P < 0.01 versus control).
4722 J. Dairou et al. / FEBS Letters 579 (2005) 4719–4723CoA. We showed that preincubation of myotube extracts
with excess AcCoA prior to peroxynitrite addition signiﬁ-
cantly protected (up to 60%) endogenous NAT2 (Fig. 4)
and NAT1 (data not shown) activity. CoA at similar con-
centrations gave no protection. These data demonstrate that
peroxynitrite modiﬁes the catalytic cysteine residue of muscle
NAT enzymes resulting in their irreversible inhibition. In
addition, these results suggest that peroxynitrite impairs
the NAT enzymes activity in muscle cells via the oxidation
of their catalytic cysteine residue to sulﬁnic and/or sulfonic
forms. This is in full agreement with the data obtained with
recombinant NAT enzymes treated by peroxynitrite [9,18]. It
has been shown that other important XME are also irrevers-
ibly impaired by peroxynitrite-dependent modiﬁcation of key
residues. For example, several cytochromes P450, such as
the 2B1 and the 3A2 isoforms, are inactivated by peroxyni-
trite through tyrosine nitration or cysteine oxidation [27,43].
Glutathione S-transferases are also inactivated by peroxyni-
trite [28]. XMEs, such as cytochromes P450, glutathione S-
transferases and nuclear receptors like the constitutive
androstane receptor (CAR), that regulate the expression of
these enzymes have been shown to be expressed in skeletal
muscle [22,24,33]. The induction of certain cytochromes
P450 in skeletal muscle has been linked to ethanol-depen-
dent rhabdomyolysis suggesting that muscle XME activities
may be involved in pathologies of this tissue [22]. Skeletal
muscle is highly susceptible to peroxynitrite generation dur-
ing muscle aging, extreme exercise, inﬂammation or septic
shock [1,4,5], with several muscle enzymes being impaired
by peroxynitrite [1,5,7]. Also, skeletal muscle may be ex-
posed to many chemicals or drugs due to its high blood ﬂow
and capacity to sequester these types of molecules [29]. Our
study suggests that generation of peroxynitrite under certain
conditions, such as inﬂammation, may contribute to muscle
dysfunction and pathologies through impairment of the bio-
transformation functions of XMEs such as NAT enzymes.
In the pharmacokinetics of many therapeutic drugs there is
potential involvement of muscle. [29] Therefore, our study
suggests that impairment of muscle NAT enzymes may be
involved in drug-dependent toxicity.Acknowledgements: This work was supported by AFM (Association
Franc¸aise contre les Myopathies), ARC (Association pour la Recher-
che contre le Cancer) and RETINA France. Julien Dairou holds a
postdoctoral fellowship from AFM. We thank Monique Casteras-
Simon for helping with cell cultures.References
[1] Lawler, J.M. and Song, W. (2002) Speciﬁc of antioxidant enzyme
inhibition in skeletal muscle to reactive nitrogen species donors.
Biochem. Biophys. Res. Commun. 294, 1093–1100.
[2] Patwell, D.M., McArdle, A., Morgan, J.E., Patridge, T.A. and
Jackson, M.J. (2004) Release of reactive oxygen and nitrogen
species from contracting skeletal muscle cells. Free Radic. Biol.
Med. 37, 1064–1072.
[3] Gutierrez-Martin, Y., Martin-Romero, F.J., Inesta-Vaquera,
F.A., Gutierrez-Merino, C. and Henao, F. (2004) Modula-
tion of sarcoplasmic reticulum Ca(2+)-ATPase by chronic
and acute exposure to peroxynitrite. Eur. J. Biochem. 271,
2647–2657.
[4] Boveris, A., Alvarez, S. and Navarro, A. (2002) The role of
mitochondrial nitric oxide synthase in inﬂammation and septic
shock. Free Radic. Biol. Med. 33, 1186–1193.
[5] Kanski, J., Alterman, M.A. and Schoneich, C. (2003) Proteomic
identiﬁcation of age-dependent protein nitration in rat skeletal
muscle. Free Radic. Biol. Med. 35, 1229–1239.
[6] Denicola, A. and Radi, R. (2005) Peroxynitrite and drug-
dependent toxicity. Toxicology 208, 273–288.
[7] Wendt, S., Schlattner, U. and Wallimann, T. (2003) Diﬀerential
eﬀects of peroxynitrite on human mitochondrial creatine kinase
isoenzymes. Inactivation, octamer destabilization, and identiﬁca-
tion of involved residues. J. Biol. Chem. 278, 1125–1130.
[8] Hein, D., McQueen, C., Grant, D., Goodfellow, G., Kadlubar, F.
and Weber, W. (2000) Pharmacogenetics of the arylamine N-
acetyltransferases: a symposium in honor of Wendell W. Weber.
Drug Metab Dispos 28, 1425–1432.
[9] Pompeo, F., Brooke, E., Akane, K., Mushtaq, A. and Sim, E.
(2002) The pharmacogenetics of NAT: structural aspects. Phar-
macogenomics 3, 19–30.
[10] Hein, D. (2002) Molecular genetics and function of NAT1 and
NAT2: role in aromatic amine metabolism and carcinogenesis.
Mutat. Res. 65, 506–507.
[11] Upton, A., Johnson, N., Sandy, J. and Sim, E. (2001) Arylamine
N-acetyltransferases-of mice, men and microorganisms. Trends
Pharmacol. Sci. 22, 140–146.
[12] Rodrigues-Lima, F. and Dupret, J.M. (2002) In silico sequence
analysis of arylamine N-acetyltransferases: evidence for an
absence of lateral gene transfer from bacteria to vertebrates and
ﬁrst description of paralogs in bacteria. Biochem. Biophys. Res.
Commun. 293, 783–792.
[13] Sim, E., Payton, M., Noble, M. and Minchin, R. (2000) An
update on genetic, structural and functional studies of arylamine
N-acetyltransferases in eucaryotes and procaryotes. Hum. Mol.
Genet. 9, 2435–2441.
[14] Dairou, J., Malecaze, F., Dupret, J.M. and Rodrigues-Lima, F.
(2005) The xenobiotic-metabolizing enzymes arylamine N-acetyl-
transferases (NAT) in human lens epithelial cells: inactivation by
cellular oxidants and UVB-induced oxidative stress. Mol. Phar-
macol. 67, 1299–1306.
[15] Wang, H., Wagner, C.R. and Hanna, P.E. (2005) Irreversible
inactivation of arylamine N-acetyltransferases in the presence of
N-hydroxy-4-acetylaminobiphenyl: a comparison of human and
hamster enzymes. Chem. Res. Toxicol. 18, 183–197.
[16] Atmane, N., Dairou, J., Paul, A., Dupret, J.M. and Rodrigues-
Lima, F. (2003) Redox regulation of the human xenobiotic
metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1).
Reversible inactivation by hydrogen peroxide. J. Biol. Chem. 278,
35086–35092.
[17] Dairou, J., Atmane, N., Rodrigues-Lima, F. and Dupret, J.M.
(2004) Peroxynitrite irreversibly inactivates the human xenobiotic-
metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in
human breast cancer cells. A cellular and mechanistic study.
J. Biol. Chem. 279, 7708–7714.
J. Dairou et al. / FEBS Letters 579 (2005) 4719–4723 4723[18] Rodrigues-Lima, F. and Dupret, J.M. (2004) Regulation of the
activity of the human drug metabolizing enzyme arylamine N-
acetyltransferase 1: role of genetic and non genetic factors. Curr.
Pharm. Des. 10, 2519–2524.
[19] Cornish, V., Pinter, K., Boukouvala, S., Johnson, N., Labrousse,
C., Payton, M., Priddle, H., Smith, A.J.H. and Sim, E. (2003)
Generation and analysis of mice with a targeted disruption of the
arylamine N-acetyltransferase type 2 gene. Pharmacogenom. J. 3,
169–177.
[20] Sugamori, K.S., Wong, S., Gaedigk, A., Yu, V., Abramovici, H.,
Rozmahel, R. and Grant, D.M. (2003) Generation and functional
characterization of arylamine N-acetyltransferase Nat1/Nat2
double-knockout mice. Mol. Pharmacol. 64, 170–179.
[21] Fretland, A.J., Doll, M.A., Gray, K., Feng, Y. and Hein, D.W.
(1997) Cloning, sequencing, and recombinant expression of
NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid)
and A/HeJ (slow) acetylator inbred mouse: functional character-
ization of the activation and deactivation of aromatic amine
carcinogens. Toxicol. Appl. Pharmacol. 142, 360–366.
[22] Smith, C., Stamm, S.C., Riggs, J.E., Stauber, W., Harsh, V.,
Gannett, P.M., Hobbs, G. and Miller, M.R. (2000) Ethanol-
mediated CYP1A1/2 induction in rat skeletal muscle tissue. Exp.
Mol. Pathol. 69, 223–232.
[23] Crosbie, S.J., Blain, P.G. and Williams, F.M. (1997) An inves-
tigation into the role of rat skeletal muscle as a site for xenobiotic
metabolism using microsomes and isolated cells. Hum. Exp.
Toxicol. 16, 138–145.
[24] Nishimura, M., Naito, S. and Yokoi, T. (2004) Tissue-speciﬁc
mRNA expression proﬁles of human nuclear receptor subfamilies.
Drug Metab. Pharmacokinet. 19, 135–149.
[25] Hussey, A.J., Kerr, L.A., Cronshaw, A.D., Harrison, D.J. and
Hayes, J.D. (1991) Variation in the expression of Mu-class
glutathione S-transferase isoenzymes from human skeletal mus-
cle. Evidence for the existence of heterodimers. Biochem. J. 273,
323–332.
[27] Lin, H., Kent, U., Zhang, H., Waskell, L. and Hollenberg, P.
(2003) Mutation of tyrosine 190 to alanine eliminates the
inactivation of cytochrome P450 2B1 by peroxynitrite. Chem.
Res. Toxicol. 16, 129–136.
[28] Wong, P., Eiserich, J., Reddy, S., Lopez, C., Cross, C. and
van der Vliet, A. (2001) Inactivation of glutathione S-
transferase by nitric oxide-derived oxidants: exploring a role
for tyrosine nitration. Arch. Biochem. Biophys. 394, 216–
228.
[29] Khazaeinia, T., Ramsey, A.A. and Tam, Y.K. (2000) The eﬀects
of exercise on the pharmacokinetics of drugs. J. Pharm. Pharm.
Sci. 3, 292–302.[30] Yaﬀe, D. and Saxel, O. (1977) Serial passaging and diﬀerentiation
of myogenic cells isolated from dystrophic mouse muscle. Nature
270, 725–727.
[31] Kaufmann, U., Kirsch, J., Irintchev, A., Wernig, A. and
Starzinski-Powitz, A. (1999) The M-cadherin catenin complex
interacts with microtubules in skeletal muscle cells: implications
for the fusion of myoblasts. J. Cell. Sci. 112 (Pt 1), 55–68.
[32] Sinclair, J.C., Delgoda, R., Noble, M.E., Jarmin, S., Goh, N.K.
and Sim, E. (1998) Puriﬁcation, characterization, and crystalliza-
tion of an N-hydroxyarylamine O-acetyltransferase from Salmo-
nella typhimurium. Protein Expr. Purif. 12, 371–380.
[33] Rodrigues-Lima, F., Cooper, R., Goudeau, B., Atmane, N.,
Chamagne, A., Butler-Browne, G., Sim, E., Vicart, P. and
Dupret, J. (2003) Skeletal muscles express the xenobiotic-metab-
olizing enzyme arylamine N-acetyltransferase. J. Histochem.
Cytochem. 51, 789–796.
[34] Radi, R., Beckman, J., Bush, K. and Freeman, B. (1991) Peroxyni-
trite oxidation of sulfhydryls. J. Biol. Chem. 266, 4244–4250.
[35] Alvarez, M.N., Trujillo, M. and Radi, R. (2002) Peroxynitrite
formation from biochemical and cellular ﬂuxes of nitric oxide and
superoxide. Methods Enzymol. 359, 353–366.
[36] Takakura, K., Beckman, J., MacMillan-Crow, L. and Crow, J.
(1999) Rapid and irreversible inactivation of protein tyrosine
phosphatases PTP1B, CD45, and LAR by peroxynitrite. Arch.
Biochem. Biophys. 369, 197–207.
[37] Percival, M., Ouellet, M., Campagnolo, C., Claveau, D. and Li,
C. (1999) Inhibition of cathepsin K by nitric oxide donors:
evidence for the formation of mixed disulﬁdes and a sulfenic acid.
Biochemistry 38, 13574–13583.
[38] Souza, J.M. and Radi, R. (1998) Glyceraldehyde-3-phosphate
dehydrogenase inactivation by peroxynitrite. Arch. Biochem.
Biophys. 360, 187–194.
[39] Butcher, N.J., Ilett, K.F. and Minchin, R.F. (2000) Inactivation
of human arylamine N-acetyltransferase 1 by the hydroxylamine
of p-aminobenzoic acid. Biochem. Pharmacol. 60, 1829–1836.
[41] Dupret, J.M. and Rodrigues-Lima, F. (2005) Structure and
regulation of the drug-metabolizing enzymes arylamine N-acetyl-
transferases. Curr. Med. Chem. 12, 311–318.
[42] Wang, H., Vath, G.M., Gleason, K.J., Hanna, P.E. and Wagner,
C.R. (2004) Probing the mechanism of hamster arylamine N-
acetyltransferase 2 acetylation by active site modiﬁcation, site-
directed mutagenesis and pre-steady state and steady state kinetic
studies. Biochemistry 43, 8234–8246.
[43] Vuppugalla, R. and Mehvar, R. (2004) Short-term inhibitory
eﬀects of nitric oxide on cytochrome P450-mediated rug metab-
olism: time dependency and reversibility proﬁles in isolated
perfused rat livers. Drug Metab. Dispos. 32, 1446–1454.
